• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Lathan Corinna was granted 78,217 shares, increasing direct ownership by 53% to 226,207 units (SEC Form 4)

    6/26/24 4:19:27 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials
    Get the next $EKSO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lathan Corinna

    (Last) (First) (Middle)
    101 GLACIER POINT
    SUITE A

    (Street)
    SAN RAFAEL CA 94901

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    EKSO BIONICS HOLDINGS, INC. [ EKSO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/06/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/06/2024 A 78,217(1)(2) A $0 226,207(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents restricted stock units ("RSUs"). Each RSU represents the economic equivalent of one share of EKSO common stock and shall be settled in shares of EKSO common stock upon vesting.
    2. This award of RSUs was granted effective June 6, 2024, the date of the Issuer's 2024 Annual Meeting of Stockholders (the "Grant Date"), pursuant to an automatic annual non-employee director grant provision approved by the Company's Board of Directors on April 13, 2021. The RSUs are scheduled to vest and settle at the earlier of the date of the next Annual Meeting of Stockholders or the one-year anniversary of the Grant Date.
    3. Includes 78,217 unvested RSUs.
    /s/ Jerome Wong, as Attorney-in-Fact 06/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EKSO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EKSO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EKSO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ekso Bionics Reports Second Quarter 2025 Financial Results

    SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into the NVIDIA Connect program, supporting Ekso's new strategic initiative to build a proprietary foundation model for human motion and to help develop and integrate related new artificial intelligence

    7/28/25 4:05:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow

    SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter of 2025 after the close of trading on Monday, July 28, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at ww

    7/21/25 4:45:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country

    SAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, is pleased to announce the launch of eksoUniversity, a new platform providing continuing education courses to physical therapists ("PTs") and physical therapy assistants ("PTAs") across the country. Most states require healthcare professionals to complete a predetermined number of continuing education units ("CEUs") within each license renewal cycle. The goal of this requirement is to maintain competency in fields that are constantly evolving. This allows providers to stay up-to-date

    7/18/25 8:00:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    SEC Filings

    View All

    SEC Form 10-Q filed by Ekso Bionics Holdings Inc.

    10-Q - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

    7/28/25 4:10:37 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

    7/28/25 4:08:07 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form S-8 filed by Ekso Bionics Holdings Inc.

    S-8 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

    5/29/25 4:29:10 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cloyd Mary Ann was granted 236,202 shares, increasing direct ownership by 107% to 456,707 units (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    5/19/25 7:07:33 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Director Lathan Corinna was granted 236,202 shares, increasing direct ownership by 104% to 462,409 units (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    5/19/25 7:07:01 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Director Li Kecheng was granted 236,202 shares, increasing direct ownership by 105% to 460,940 units (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    5/19/25 7:06:28 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lathan Corinna bought $15,477 worth of shares (13,733 units at $1.13), increasing direct ownership by 10% to 147,990 units (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    3/14/24 6:41:52 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Leadership Updates

    Live Leadership Updates

    View All

    Ekso Bionics Accepted into NVIDIA Connect Program

    Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

    5/15/25 7:45:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

    Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. "We are pleased to strengthen our Board with the addition of Deborah Lafer Scher, a distinguished leader who brings a wealth of healthcare experience and a proven track record of business development expertise," said Scott Davis, President and Chie

    6/17/24 4:05:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation

    Broadens Ekso Bionics' product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the acquisition of the Human Motion and Control ("HMC") Business Unit from Parker Hannifin Corporation ("Parker"), a global leader in motion and control technologies. The acquisiti

    12/5/22 8:37:01 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

    SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    11/14/24 3:29:01 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Ekso Bionics Holdings Inc. (Amendment)

    SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    2/11/22 6:17:59 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed

    SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    2/12/21 10:16:25 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Financials

    Live finance-specific insights

    View All

    Ekso Bionics Reports Second Quarter 2025 Financial Results

    SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into the NVIDIA Connect program, supporting Ekso's new strategic initiative to build a proprietary foundation model for human motion and to help develop and integrate related new artificial intelligence

    7/28/25 4:05:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow

    SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter of 2025 after the close of trading on Monday, July 28, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at ww

    7/21/25 4:45:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics Reports First Quarter 2025 Financial Results

    SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

    5/5/25 4:05:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials